Please assess the completion status of the following clinical trial:

Trial Title: Effects of Atorvastatin in Graves' Orbitopathy (GO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
1. Informed consent~2. A diagnosis of Graves' disease~3. A moderately severe GO~4. Active GO~5. No corticosteroids or immunosuppressive treatment for GO in the last 3 months.~6. No previous surgical treatment for GO~7. No contraindication to GC~8. Male and female patients of age: 18-75 years~9. LDL-cholesterol levels of 115-189 mg/dl~10. No more than one cardiovascular risk factor (diabetes, high blood pressure, smoking, familial history of acute cardiovascular events, obesity)~11. Effective method of contraception~12. No mental illness that prevent patients from comprehensive, written informed consent~13. Compliant patient, regular follow-up possible~Exclusion Criteria:~1. lack of informed consent~2. Absence of Graves' hyperthyroidism (present or past)~3. Inactive GO~4. Optic neuropathy~5. Corticosteroids or immunosuppressive treatment for GO in the last 3 months.~6. Previous surgical treatment for GO~7. Contraindications to GC~8. Pregnancy, breast-feeding women~9. Acute or chronic liver disease~10. Hypersensitivity to atorvastatin or other statins, or hypersensitivity or intolerance to the medication excipients such as lactose.~11. Medications interfering/interacting with statins (CYP3A4 inhibitors or inductors)~12. Relevant Malignancy~13. Corticosteroids or other immunosuppressive agents within last 3 months~14. Recent (≤1 year) history of alcoholism or drug abuse~15. Clinical ASCVD (AthroSclerotic CardioVascular Disease)~16. LDL-cholesterol levels ≥190 mg/dl or presence of more than one associated cardiovascular risk factor (diabetes, high blood pressure, smoking, familial history of acute cardiovascular events, obesity)~17. Severe familial hyperlipemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Statins (Type: EXPERIMENTAL): Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
- No statins (Type: ACTIVE_COMPARATOR): Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).